ArticleCureus2025
Early Recognition and Management of Arrhythmogenic Right Ventricular Cardiomyopathy in a Young Athlete: A Case Report Highlighting the Role of Multimodal Diagnosis and Preventive Implantable Cardioverter Defibrillator (ICD) Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a rare inherited cardiomyopathy marked by fibrofatty replacement of right ventricular (RV) myocardium, leading to electrical instability and increased risk for ventricular arrhythmias and sudden cardiac death (SCD). ARVC is typically inherited in an autosomal dominant pattern and often involves mutations in desmosomal proteins such as plakophilin-2 (PKP2). Clinical presentation can vary from asymptomatic to life-threatening arrhythmias, particularly among young athletes. This case emphasizes the importance of early detection and intervention in patients with ARVC. A 21-year-old previously healthy male presented with recurrent exertional syncope. Initial ECG demonstrated sinus rhythm with T-wave inversions in leads V1-V3. Coronary CT angiography and resting echocardiography were normal. However, the stress electrocardiogram revealed frequent premature ventricular complexes (PVCs) with a left bundle branch block morphology. Ambulatory event monitoring detected over 500 monomorphic PVCs in a 24-hour period. Cardiac MRI demonstrated mildly reduced RVEF (39%) with regional dyskinesia, meeting major diagnostic criteria per the 2010 Task Force Criteria for ARVC. Genetic testing confirmed a heterozygous pathogenic mutation (c.1689-1G>C) in the PKP2 gene. The patient was started on beta-blockers and underwent implantation of a single-chamber implantable cardioverter defibrillator (ICD) due to elevated arrhythmic risk. Post-implantation, the ICD successfully terminated three episodes of ventricular tachycardia, highlighting its life-saving role. This case underscores the necessity for a high index of suspicion when evaluating young patients with unexplained syncope or arrhythmias. Diagnosis of ARVC requires integration of clinical, electrocardiographic, imaging, and genetic data. Early diagnosis and prompt management, including activity modification, pharmacologic therapy, and ICD implantation, are critical to mitigating the risk of SCD. Genetic testing and vigilant follow-up remain essential components in the care of ARVC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.